Merck Animal Health to acquire Elanco's aqua business for ~$1.3B

Elanco Acquires Kindred Biosciences

June 16, 2021

Biotechnology

Elanco Animal Health acquired all outstanding stock of Kindred Biosciences for $9.25 per share (approximately $440–444 million), strengthening Elanco's biologics and monoclonal antibody R&D capabilities. The deal adds KindredBio's pipeline — including three potential dermatology blockbusters expected through 2025 — and is expected to contribute roughly $100 million to Elanco's innovation revenue outlook by 2025.

Elanco Animal Health Acquires Aratana Therapeutics

July 18, 2019

Pharmaceuticals

Elanco Animal Health Incorporated completed its acquisition of Aratana Therapeutics, a developer and commercializer of specialty therapeutics for dogs and cats, including Galliprant, Entyce and Nocita. The deal expands Elanco's companion animal product portfolio and establishes a dedicated specialty veterinary commercial team to integrate Aratana's field force and pipeline.

Merck Animal Health Acquires Vence

September 22, 2022

Agriculture

Merck Animal Health agreed to acquire Vence, a developer of virtual fencing and livestock management technology, from Vence's founders and shareholders. The acquisition (terms undisclosed) expands Merck Animal Health's animal intelligence and precision livestock management capabilities and was expected to close in the third quarter of 2022.

Platinum Equity Acquires Lonza's Water Care Business

February 28, 2019

Manufacturing

Platinum Equity completed the acquisition of Lonza's water care business in a transaction valued at approximately $630 million. Headquartered in Alpharetta, Georgia, the business operates six production facilities across North America, South America and EMEA and supplies consumer pool-care brands and industrial/municipal water treatment solutions; Platinum Equity will operate it as a standalone platform and will announce a new corporate identity.

Swedencare AB (publ) Acquires Animal Pharmaceuticals Inc.

September 24, 2020

Veterinary

Swedencare AB (publ) acquired the operations of US-based Animal Pharmaceuticals Inc. for an initial purchase price of USD 15 million (approx. 131 million SEK) plus a potential earnout of up to USD 10 million; consideration includes cash and a directed new share issue. The deal (closed via newly established US subsidiary Animal Pharm Care USA, Inc.) adds a portfolio of supplements and topical veterinary products sold to ~8,500 US veterinary clinics and positions founder Jason Braun to lead the business and become a major Swedencare shareholder.

Elanco Acquires Prevtec Microbia

August 1, 2019

Biotechnology

Elanco Animal Health acquired Montreal-based Prevtec Microbia, maker of the Coliprotec swine E. coli vaccine line, in an all-cash transaction of CAD $78.5 million (approx. $59.9M USD) plus contingent payments of up to CAD $21.5 million. The deal brings Prevtec's commercial vaccines and R&D pipeline into Elanco to expand its swine portfolio and provide non-antibiotic alternatives for swine producers globally.